ReviewThe protein journal2025
Effect of Mutations on the Evolution of Extended Spectrum β-lactamases (ESBL).
Review in The protein journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial antimicrobial resistance is a great public health threat worldwide, a situation that is much escalated by the rapid propagation of Extended Spectrum β-lactamase (ESBL) enzymes. These can hydrolyze and inactivate a broad range of β-lactams, including third-generation cephalosporins, penicillin, and aztreonam and are known to be associated with various bacterial infections, ranging from uncomplicated urinary tract infections to life-threatening sepsis.Variation is the essential raw material of Darwinian evolution and the accumulation of mutations plays one of the most important roles in it. Sequential acquisition of spontaneous mutations followed by successive rounds of selection can be attributed as one of the major reasons for the rapid diversification of ESBL enzymes. The ESBLs are excellent examples of 'microevolution' that led to 'gain-of-function' with an extended substrate spectrum. However, acquiring newer phenotypes sometimes comes with fitness costs and different mutational pathways interact with each other, triggering both additive and non-additive fitness to generate a rugged fitness landscape, that influences the path a strain must follow to adapt and evolve under selection pressure. Therefore, it is important to understand the role of mutations in the emergence of these enzyme variants. This review focuses on the understanding of different facades of mutational pathways that lead to the adaptive evolution of ESBL phenotype. The structural and mechanistic basis of the extension of the substrate spectrum by mutations are also discussed.
Indexed as
Identifiers
40830675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.